The study involved 2,011 severely ill COVID-19 patients across 129 sites in four countries, including the U.S. About half received two units of high-titer convalescent plasma, while the other half did not.
Treatment with convalescent plasma did not significantly reduce the number of days spent on life support, findings showed.
“Among critically ill adults with confirmed COVID-19, treatment with convalescent plasma had a low likelihood of providing improvement in organ support-free days,” researchers said.
The in-hospital mortality rate for the convalescent plasma group was 37.3 percent and slightly higher at 38.4 percent among those who didn’t receive it.
For both groups, the median number of days alive and free of organ support was 14.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
